6 million potential patients times $150,000 per patient equals $900 billion. Assume it takes 20 years to implant existing potential patients, that means $45 billion in annual revenue. Assume they only reach 10% of the potential market, then that equals $4.5 billion in annual revenue.
Orion 1 could reach the marketplace in 2020. In between now and then this company has an existing product to produce revenues for macular degeneration. Shouldn't this be a $50 stock right now?